These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 20195772)

  • 1. Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus.
    Joffe HV; Parks MH; Temple R
    Rev Endocr Metab Disord; 2010 Mar; 11(1):21-30. PubMed ID: 20195772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
    Sharma A; Pagidipati NJ; Califf RM; McGuire DK; Green JB; Demets D; George JT; Gerstein HC; Hobbs T; Holman RR; Lawson FC; Leiter LA; Pfeffer MA; Reusch J; Riesmeyer JS; Roe MT; Rosenberg Y; Temple R; Wiviott S; McMurray J; Granger C
    Circulation; 2020 Mar; 141(10):843-862. PubMed ID: 31992065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.
    Azim S; Baker WL; White WB
    Curr Cardiol Rep; 2014 Nov; 16(11):541. PubMed ID: 25303895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.
    Gourgari E; Wilhelm EE; Hassanzadeh H; Aroda VR; Shoulson I
    J Diabetes Complications; 2017 Dec; 31(12):1719-1727. PubMed ID: 28939018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.
    McGuire DK; Marx N; Johansen OE; Inzucchi SE; Rosenstock J; George JT
    Diabetes Obes Metab; 2019 May; 21(5):1073-1078. PubMed ID: 30690856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reflections on using non-inferiority randomised placebo controlled trials in assessing cardiovascular safety of new agents for treatment of type 2 diabetes.
    Campbell-Scherer D
    Evid Based Med; 2017 Apr; 22(2):54-56. PubMed ID: 28274954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the cardiovascular safety of diabetes therapies.
    Goldfine AB
    N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
    [No Abstract]   [Full Text] [Related]  

  • 8. Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?
    Lipska KJ; Krumholz HM
    JAMA; 2017 Mar; 317(10):1017-1018. PubMed ID: 28125758
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular Safety Trials for All New Diabetes Mellitus Drugs?
    Low Wang CC; Everett BM; Burman KD; Wilson PWF
    Circulation; 2019 Apr; 139(14):1741-1743. PubMed ID: 30933621
    [No Abstract]   [Full Text] [Related]  

  • 10. Beyond HbA1c.
    Bloomgarden Z
    J Diabetes; 2017 Dec; 9(12):1052-1053. PubMed ID: 28792665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone and the FDA.
    Joffe HV; Parks MH; Meyer RJ; Jenkins JK; Temple R
    N Engl J Med; 2007 Oct; 357(17):1775-6; author reply 1777. PubMed ID: 17761586
    [No Abstract]   [Full Text] [Related]  

  • 12. Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity?
    Khunti K; Davies MJ; Marx N; Buse JB
    Lancet Diabetes Endocrinol; 2020 Oct; 8(10):810-811. PubMed ID: 32946819
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDA.
    Chong WH; Yanoff LB; Andraca-Carrera E; Thanh Hai M
    N Engl J Med; 2020 Sep; 383(13):1199-1202. PubMed ID: 32966719
    [No Abstract]   [Full Text] [Related]  

  • 14. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus.
    Genuth S
    Ann Intern Med; 1996 Jan; 124(1 Pt 2):104-9. PubMed ID: 8554200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.
    Chawla AJ; Mytelka DS; McBride SD; Nellesen D; Elkins BR; Ball DE; Kalsekar A; Towse A; Garrison LP
    Pharmacoepidemiol Drug Saf; 2014 Mar; 23(3):268-77. PubMed ID: 24892175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand model.
    Monte SV; Schentag JJ; Adelman MH; Paladino JA
    J Diabetes Sci Technol; 2010 Mar; 4(2):382-90. PubMed ID: 20307400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory watch: FDA issues guidance for cardiovascular risk assessment of novel antidiabetic agents.
    Nat Rev Drug Discov; 2009 Feb; 8(2):99. PubMed ID: 19180100
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
    Nissen SE; Wolski K; Topol EJ
    JAMA; 2005 Nov; 294(20):2581-6. PubMed ID: 16239637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?
    Lovre D; Htun W; Carrion C; Fonseca VA
    Curr Diab Rep; 2016 Oct; 16(10):94. PubMed ID: 27541296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.